Welcome to our dedicated page for Inovio Pharmaceuticals news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceuticals stock.
Inovio Pharmaceuticals reports developments in DNA medicines for HPV-related diseases, cancer and infectious diseases. Its updates center on INO-3107, a DNA immunotherapy candidate for recurrent respiratory papillomatosis, including clinical data, scientific publications, FDA review milestones and presentations at medical and biotechnology conferences.
Company news also includes quarterly and annual financial results, business updates, research on DNA-encoded monoclonal antibodies and DNA-encoded protein technology, collaboration activity and capital-structure actions involving common stock, warrants and at-the-market financing programs.
INOVIO (NASDAQ: INO) has appointed Gene Kim as President of INOVIO Asia and Mammen Mammen as Senior VP of Clinical Development. Mr. Kim, with extensive CFO experience in Korean firms, will drive corporate development in Asia, particularly South Korea. Dr. Mammen, an expert in military vaccines, will oversee clinical development for INO-4800, the company's COVID-19 DNA vaccine. INO-4800 is notable for its stability at room temperature, crucial for mass immunization efforts. INOVIO continues to advance its DNA medicine platform with 15 clinical programs targeting various diseases.